News »November 2006

Acomplia- New Avenue in Diabetes Management

November 09, 2006

A new study reports that diet drug Acomplia (Rimonabant) may help in controlling sugar levels in type-2 diabetes, offering a new opportunity in diabetes management.

One year long RIO- Diabetes trial, found that Acomplia (Rimonabant) considerably improved several cardiometabolic risk factors in patients whose diabetes was uncontrolled.

50% of the improvements in HbA1c and HDL-cholesterol levels were independent of the weight loss achieved, indicating a direct effect of rimonabant on these parameters, say authors.

Most of the medications for type-2 diabetes are associated with weight gain, findings support that use of 20 mg per day of rimonabant, in addition to regular diet and exercise, is a new approach to reduce body weight and improve blood glucose control in overweight.

In a patient population where control or lowering is often difficult to gain, Acomplia (Rimonabant) was able to reduce blood sugar levels.

Rimonabat is the first drug to block cannabinoid, thus inhibiting appetite and leading to weight loss.